Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SIM0270 Drug-Drug Interaction Study in Healthy Chinese Adults
NCT07357610Phase 1Recruiting
- Sponsor
- Simcere Pharmaceutical Group
- Start
- Jan 2026
- Primary completion
- Oct 2026
- Modality
- Molecular Glues
- Countries
- 1
01
Overview
Phase 1, open-label trial of SIM0270 in breast cancer, sponsored by Simcere Pharmaceutical Group. Primary endpoints: Maximum observed concentration of SIM0270, Area under concentration curve from time 0 to the last quantifiable concentration of SIM0270 and 5 more. Started Jan 2026; status: recruiting.
02
Drugs
SIM0270
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT07357610.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07357610.